ReviewFrontiers in pharmacology2022
Efficacy of Osteoporosis Medications for Patients With Chronic Kidney Disease: An Updated Systematic Review and Network Meta-Analysis.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.Frontiers in pharmacology · 2025Pooled it
- Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease.Journal of endocrinological investigation · 2026Review
- Bone Mineral Density and the Risk of Fracture According to eGFR in Postmenopausal Women.Journal of the American Society of Nephrology : JASN · 2026Article
- Common Gynecologic Issues in Patients Post-Kidney Transplantation.Clinical transplantation · 2026Review
- Article
- Efficacy of 12-month romosozumab monotherapy or combination with eldecalcitol in patients with osteoporosis with and without chronic kidney disease: A real-world retrospective study.Biomedical reports · 2025Article
- Management of osteoporosis in chronic kidney disease.Clinical kidney journal · 2025Review
- Article
- The Management of Osteoporosis in Chronic Kidney Disease: A Review of Diagnostic and Therapeutic Approaches.Cureus · 2024Review
- Monoclonal antibodies in patients with osteoporosis and renal insufficiency: An updated systematic review and meta-analysis.Osteoporosis and sarcopenia · 2024Review
- The Molecular Mechanisms Underlying the Systemic Effects Mediated by Parathormone in the Context of Chronic Kidney Disease.Current issues in molecular biology · 2024Review
- Management of fracture risk in CKD-traditional and novel approaches.Clinical kidney journal · 2023Review
- Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review.Risk management and healthcare policy · 2023Review
- Is Adynamic Bone Always a Disease? Lessons from Patients with Chronic Kidney Disease.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.